RxDoctor Payments Data

James Tollefson, DO

Cardiovascular Disease · Ogden, UTNPI 1366806986

Payments from drug & device makers

$1,352in general payments, 2019–2025

Across 25 payments — averaging $54.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$301
  • Abbott$284
  • Terumo Medical Corporation$260
  • Medtronic$253
  • Astellas Pharma US Inc$129
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$46
  • plus $79 from 4 others

What the payments were for

  • Food & beverage$70652%
  • Education$64648%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,352 in reported general payments places this provider in the 40th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah

Medicare billing

Part B allowed, 2024
$70,728
Medicare patients
648
Services billed
1,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$72,494
FarxigaDapagliflozin Propanediol45$47,894
EntrestoSacubitril/Valsartan22$26,504
Repatha SureclickEvolocumab28$19,784
Potassium Chloride84$1,692
Metoprolol Succinate94$1,483
Bumetanide37$1,387
Atorvastatin Calcium78$1,067
Ranolazine ErRanolazine14$929
Losartan Potassium71$869
Chlorthalidone28$586
Spironolactone74$529
Nitroglycerin19$349
Torsemide15$315
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$72,49454 claims
AstraZenecaFarxiga$301$47,89445 claims
NovartisEntresto$19$26,50422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 131 cardiovascular disease providers in Utah.

Other cardiovascular disease in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →